이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases

2026년 5월 20일 업데이트: Xingchen Peng, West China Hospital

A Phase I Clinical Trial of YMN-A02 in Patients With Advanced pMMR Colorectal Cancer and Liver Metastases: Safety, Tolerability, and Preliminary Efficacy

This study was a prospective, single-center, open-label, single-arm, multi-dose ascending phase Ⅰ clinical trial. The investigators constructed a TM10-LNP mRNA preparation encoding CTLA-4 antibody and TGF-β trap bifunction protein (YMN-A02 bifunction RNA preparation). The aim of this study is to provide a new strategy for overcoming the immune tolerance of liver tumors and improving the response rate of immunotherapy. The investigators planned to enroll patients with advanced pMMR liver metastasis from colorectal cancer who failed standard treatment. A modified "3+3" design was used, and 10 patients were expected to be enrolled. There were four dose groups of 100μg, 250μg, 500μg and 1000μg. The trial used a modified "3+3" dose climbing design, in which one subject was set as a sentinel patient in the initial 100μg dose group. If the subject did not experience DLT during the DLT observation period, the dose was judged safe and escalation to the next group occurred. If DLT occurred, 3 additional subjects in this group would be required for further evaluation. In the subsequent 250μg, 500μg, and 1000μg dose groups, three subjects were enrolled first in each group: if there was no DLT, the number of subjects was increased. If ≥2 of the 3 cases had DLT, the escalation was terminated. If DLT occurred in 1 out of 3 subjects, 3 additional observations would be made in the same dose group. If the incidence of DLT in the total 6 subjects did not exceed 1/6 after the supplement, the escalation could be escalated. Otherwise, the escalation was terminated and the dose was considered as intolerable.

연구 개요

연구 유형

중재적

등록 (추정된)

10

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Peng Xingchen Peng
  • 전화번호: 86-17723609529
  • 이메일: pxx2014@163.com

연구 장소

    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • West China Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Signed the informed consent form approved by the ethics committee.
  2. 18-70 years old; ECOG performance status 0-1.
  3. Histologically or cytologically confirmed colorectal cancer with liver metastases, molecularly classified as pMMR (presence of other distant metastases allowed).
  4. Patients who have failed or are intolerant to standard therapy, or who refuse standard therapy.

    1. For patients with RAS/BRAF wild-type and eligible for targeted therapy: enrollment allowed only after disease progression on a prior standard regimen containing anti-EGFR or anti-VEGF monoclonal antibody.
    2. For patients with BRAF V600E mutation: enrollment allowed only after failure of a prior BRAF inhibitor-containing chemotherapy regimen.
    3. For patients who do not meet the above molecular characteristics: enrollment allowed only after failure of at least two prior lines of systemic chemotherapy (including a platinum-containing regimen).
  5. At least one measurable liver metastasis (CT scan long diameter ≥10 mm, slice thickness ≤5 mm).
  6. Life Expectancy≥3 months.
  7. Adequate Major Organ Function (all within 14 days before randomization):

    1. Hemoglobin ≥80 g/L (no transfusion within 14 days); absolute neutrophil count >1.5×10⁹/L; platelet count ≥80×10⁹/L.
    2. Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN (or ≤5×ULN in the presence of liver metastases); creatinine clearance ≥60 mL/min (Cockcroft-Gault formula).
    3. Left ventricular ejection fraction (LVEF) ≥50%.
  8. Good compliance, and family agrees to cooperate with survival follow-up.

Exclusion Criteria:

  1. Participation in another interventional drug trial within 4 weeks before enrollment.
  2. Prior or concurrent other malignancy, except: carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, superficial bladder tumor, or any other malignancy that has been curatively treated and recurrence-free for ≥5 years.
  3. Poorly controlled heart disease or clinical symptoms, including but not limited to: NYHA class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
  4. Pregnant or breastfeeding women.
  5. Active infection, including but not limited to: active tuberculosis, systemic bacterial or fungal infection (NCI-CTCAE v5.0 grade ≥2), HIV infection, active HBV (HBV DNA >ULN), or active HCV (HCV RNA >ULN).
  6. History of substance abuse that cannot be abstained from, or history of psychiatric disorders.
  7. Active or history of autoimmune disease (including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism, etc.). Exceptions: vitiligo controlled with only topical agents; childhood asthma completely resolved without any intervention in adulthood. Patients with asthma requiring bronchodilators for medical intervention are excluded.
  8. Prior vaccination with any mRNA-based drug or mRNA formulation.
  9. Prior participation in any clinical trial involving lipid nanoparticle (LNP) formulations.
  10. Contraindications to intravenous infusion.
  11. History of drug abuse, or any medical, psychological, or social condition (e.g., alcoholism or drug addiction) that, in the investigator's judgment, may affect study compliance.
  12. Known allergy, hypersensitivity, or intolerance to any component (active substance or excipients) of the study drug; history of severe allergy to drugs, food, or vaccines, including but not limited to anaphylactic shock, angioedema of the larynx, anaphylactic dyspnea, allergic purpura, thrombocytopenic purpura, or Arthus reaction.
  13. Plan to conceive (either female subject or partner of male subject) from screening through 12 months after the last dose.
  14. Any concurrent condition that, in the investigator's judgment, may compromise patient safety or interfere with study completion.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: YMN-A02 100 μg Group
Enrolled subjects will receive a 100 μg intravenous infusion.
Enrolled subjects will receive a 100 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.
다른 이름들:
  • YMN-A02
실험적: YMN-A02 250 μg Group
Enrolled subjects will receive a 250 μg intravenous infusion.
Enrolled subjects will receive a 250 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.
실험적: YMN-A02 500 μg Group
Enrolled subjects will receive a 500 μg intravenous infusion.
Enrolled subjects will receive a 500 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.
실험적: YMN-A02 1000 μg Group
Enrolled subjects will receive a 1000 μg intravenous infusion.
Enrolled subjects will receive a 1000 μg intravenous infusion according to their assigned dose group. The dosing regimen includes 5 doses of primary immunization followed by subsequent individualized treatment. The first 4 doses of primary immunization are administered once weekly (Q1W), and the 5th dose is administered one month after the 4th dose. The DLT observation period is from the first infusion to 14 days after the third infusion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Occurrence of Dose-Limiting Toxicity (DLT)
기간: From first dose to 14 days after the third dose, approximately Day 0 to Day 42
Observe and record the occurrence of DLTs. DLT is defined as treatment-related adverse events or clinically significant laboratory abnormalities occurring during the DLT observation period, graded according to NCI CTCAE v5.0.
From first dose to 14 days after the third dose, approximately Day 0 to Day 42

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS)
기간: Within 2 years after the first dose
Assess disease progression per RECIST v1.1, calculating the time from start of treatment to first documented disease progression or death from any cause.
Within 2 years after the first dose
Objective Response Rate (ORR)
기간: Within 6 months after the first dose
Tumor response assessed per RECIST v1.1 for solid tumors. ORR is the proportion of patients whose tumor volume reduction reaches a predefined value and is maintained for a minimum required duration, calculated as the sum of complete response (CR) and partial response (PR) rates.
Within 6 months after the first dose

기타 결과 측정

결과 측정
측정값 설명
기간
Changes in Peripheral Blood Lymphocyte Subsets
기간: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Peripheral blood lymphocytes will be isolated from whole blood using lymphocyte separation medium. Flow cytometry will be used to detect T cells, B cells, macrophages, NK cells, and regulatory T cells (Tregs).
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Percentage of Dendritic Cells Expressing Maturation/Activation Markers
기간: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Dendritic cells (DCs) will be isolated from peripheral blood and labeled with antibodies against surface markers CD80, CD86, and MHC class II molecules. Flow cytometry will be performed to determine the percentage of DCs positive for each marker. Maturation and activation status are assessed based on these percentages
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Tumor-Infiltrating CD8+ T Cells
기간: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Tumor tissue sections will be stained to identify CD8+ T cells, including stem-like and exhausted CD8+ T cell subsets. Confocal microscopy and flow cytometry (using single-cell suspensions from tumor tissue) will be used to observe the infiltration status of these cells.
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Cytokine Levels Associated with Delayed-Type Hypersensitivity (DTH)
기간: Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)
Plasma will be collected 24-72 hours after administration. ELISA kits will be used to measure the levels of cytokines including IL-12, IFN-γ, IL-2, and IL-10 to assess the cellular immune response and the impact of the product on immune function.
Baseline (Day 1 pre-infusion); Day 8 (before the 2nd infusion); Day 22 (before the 4th infusion); Days 29-36 (7-14 days after the 4th infusion); Days 41-55 (19-33 days after the 4th infusion)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 30일

기본 완료 (추정된)

2028년 6월 30일

연구 완료 (추정된)

2028년 6월 30일

연구 등록 날짜

최초 제출

2026년 4월 26일

QC 기준을 충족하는 최초 제출

2026년 5월 20일

처음 게시됨 (실제)

2026년 5월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 20일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2026(890)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다